Science.
Innovation.
Quality.
Bringing accessible, high-quality medicines to market requires precision and vision.
We deliver value to patients, providers, and payers
without compromising quality standards.
Amneal Biosciences grew out of Amneal’s extensive experience in the research, development, manufacturing, and distribution of high-quality medicines.*
*The National Association of Boards of Pharmacy Drug Distributor Accreditation acknowledges Amneal’s commitment to excellence in pharmaceuticals.
Quality is a core value of
our organization.
— Chintu Patel
Co-CEO, Co-Founder of Amneal Pharmaceuticals
Amneal’s global presence†
Amneal’s global presence†
North America
Branchburg, NJ, USA
Oral Liquid Products, Nasal Sprays
Bridgewater, NJ, USA
Headquarters, Specialty/Complex R&D
Brookhaven, NY, USA
Oral Solids, Soft Gel, High Potency and Hormonal Products
Glasgow, KY, USA
Sales Operations, Distribution
Europe
Cashel, Ireland
Inhalation
Asia
Ahmedabad, India
5 Facilities: 2 Oral Solids, 3 Injectables
Dahej, India
Active Pharmaceutical Ingredients (API)
Hyderabad, India
Oncology
Mumbai, India
Commercial Offices
Vizag, India
Active Pharmaceutical Ingredients (API)
†All information is presented as of May 20, 2024.
Amneal’s direct manufacturing facilities in the United States and India, and partners in the United States, Canada, China, and Europe enable us to be agile, efficient, and cost-effective.
‡Across multiple dosage forms.
We are proud to work with our biosimilars partners.
ALYMSYS® (bevacizumab-maly)
RELEUKO® (filgrastim-ayow)
FYLNETRA® (pegfilgrastim-pbbk)
Interested in a virtual tour inside the facility where ALYMSYS® is made?
Committed to supporting a sustainable supply chain
Amneal supported the creation of a bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus in the US House of Representatives, which focuses on securing America’s pharmaceutical supply chain by ensuring that critical medicines are manufactured in the United States.
“The pandemic and Ukraine war have highlighted the vital importance of a sustainable supply chain in the pharmaceutical industry. From raw materials to finished products, domestic manufacturing is critical for our US supply chain and national security. We fully support the prioritization of essential medicines to be made in America. We see the formation of this caucus as a key step towards the potential for a more permanent legislative solution that can drive meaningful change across our supply chain.”
— Chirag and Chintu Patel, Co-Chief
Executive Officers